Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The 2022 Tandem Meetings
🎥 Alexander Perl (@PennMedicine) provides insight into the VICEROY study, a trial evaluating the efficacy, safety, &optimal dosing of the VEN/AZA/GILT triplet regimen in pts with newly diagnosed FLT3-mutated AML:
👉 👈
#AMLsm #Leusm #ASH25 #TrialUpdate…
The VICEROY study: VEN/AZA/GILT in newly diagnosed FLT3-mutated AML
In this video, Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, provides insight into the Phase I/II ...
ow.ly
In an interview from #ASH25, Daniel Wiseman of @OfficialUoM shares results from the Phase II AMMO trial, comparing ASTX727 (oral decitabine-cedazuridine) to hydroxycarbamide/best supportive care in CMML and other MDS/MPN overlap syndromes.
Watch now:
🎥 …
Findings from the Phase II AMMO trial of ASTX727 in CMML and other MDS/MPN overlap syndromes
Daniel Wiseman, MBBS, PhD, University of Manchester, Manchester, UK, discusses results of the Phase II AMMO trial (I...
ow.ly
#ASH25 | @RabiHannaMD of @ClevelandClinic shares updated results from the RUBY trial, which is investigating reni-cel, an investigational gene-edited autologous hematopoietic stem cell therapy, in patients with severe #SickleCellDisease:
🎥 ➡️ …
Reni-cel in severe SCD: updated results from the RUBY trial
Rabi Hanna, MD, Cleveland Clinic, Cleveland, OH, shares updated results from the RUBY trial (NCT04853576), which is ...
ow.ly
It was great to catch up with Hans Lee (@SarahCannonDocs) at #ASH25, to hear his highlights in #MultipleMyeloma!
🎥 👉
Dr Lee mentions several key trials presented (MAJESTEC-3, IFM2021-01, & IMMUNOPLANT) and notes the emerging theme of earlier…
Bispecific antibodies in myeloma: top trial updates from ASH 2025
In this video, Hans Lee, MD, Sarah Cannon Research Institute, Nashville, TN, discusses his highlights in multiple my...
ow.ly
Want to hear about the potential factors influencing the lack of survival benefit observed in the Phase III VERONA trial of venetoclax plus azacitidine in newly diagnosed HR-MDS?🤔
Then don't miss our interview with Jacqueline Garcia of @DanaFarber from #ASH25:
🎥…
The 2022 Tandem Meetings
🎥 Alexander Perl (@PennMedicine) provides insight into the VICEROY study, a trial evaluating the efficacy, safety, &optimal dosing of the VEN/AZA/GILT triplet regimen in pts with newly diagnosed FLT3-mutated AML:
👉 👈
#AMLsm #Leusm #ASH25 #TrialUpdate…
The VICEROY study: VEN/AZA/GILT in newly diagnosed FLT3-mutated AML
In this video, Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, provides insight into the Phase I/II ...
ow.ly
In an interview from #ASH25, Daniel Wiseman of @OfficialUoM shares results from the Phase II AMMO trial, comparing ASTX727 (oral decitabine-cedazuridine) to hydroxycarbamide/best supportive care in CMML and other MDS/MPN overlap syndromes.
Watch now:
🎥 …
Findings from the Phase II AMMO trial of ASTX727 in CMML and other MDS/MPN overlap syndromes
Daniel Wiseman, MBBS, PhD, University of Manchester, Manchester, UK, discusses results of the Phase II AMMO trial (I...
ow.ly
#ASH25 | @RabiHannaMD of @ClevelandClinic shares updated results from the RUBY trial, which is investigating reni-cel, an investigational gene-edited autologous hematopoietic stem cell therapy, in patients with severe #SickleCellDisease:
🎥 ➡️ …
Reni-cel in severe SCD: updated results from the RUBY trial
Rabi Hanna, MD, Cleveland Clinic, Cleveland, OH, shares updated results from the RUBY trial (NCT04853576), which is ...
ow.ly
It was great to catch up with Hans Lee (@SarahCannonDocs) at #ASH25, to hear his highlights in #MultipleMyeloma!
🎥 👉
Dr Lee mentions several key trials presented (MAJESTEC-3, IFM2021-01, & IMMUNOPLANT) and notes the emerging theme of earlier…
Bispecific antibodies in myeloma: top trial updates from ASH 2025
In this video, Hans Lee, MD, Sarah Cannon Research Institute, Nashville, TN, discusses his highlights in multiple my...
ow.ly
Want to hear about the potential factors influencing the lack of survival benefit observed in the Phase III VERONA trial of venetoclax plus azacitidine in newly diagnosed HR-MDS?🤔
Then don't miss our interview with Jacqueline Garcia of @DanaFarber from #ASH25:
🎥…
